Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.43 |
| ▸ | KDM4A | O75164 | 12/20 | 0.43 |
| ▸ | KDM5A | P29375 | 6/20 | 0.43 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944839 | 0.77 | KDM5A (0.57) | KDM4CKDM4AKDM5AKDM7APHF8 | |
| SCHEMBL14944835 | 0.74 | ALDH1A1 (0.47) | KDM4AALDH1A1CHRM1PAOX | |
| SCHEMBL519505 | 0.73 | — | — | |
| SCHEMBL14944833 | 0.72 | ALDH1A1 (0.46) | KDM4CKDM4AKDM5AKDM7APHF8 | |
| SCHEMBL8186197 | 0.72 | LMNA (0.39) | KDM4CKDM4AKDM5AKDM7APHF8 | |
| SCHEMBL14944840 | 0.71 | KDM4A (0.58) | KDM4CKDM4AKDM5APHF8KDM2A | |
| Bromide SCHEMBL11714940 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL167380 | 0.71 | — | — | |
| SCHEMBL2217350 | 0.70 | — | — | |
| SCHEMBL3357906 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM4C 20/4885KDM4A 9/4885KDM5A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.